Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 341

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 341
---
-of-use assets and lease liabilities

    175

    194

    Inventory

    (6,142
    )

    (9,442
    )

    Other long-term assets

    —

    (1,394
    )

    Net cash used in operating activities

    (266,770
    )

    (137,580
    )

    Cash flows from investing activities

    Cash paid for property and equipment

    (135
    )

    (1,634
    )

    Net cash used in investing activities

    (135
    )

    (1,634
    )

    Cash flows from financing activities

    Proceeds from issuance of common stock from exercise of stock options

    1,599

    124

    Net proceeds from issuance of debt

    59,400

    39,318

    Net proceeds from underwritten public offering

    121,775

    141,390

    Net proceeds from revenue interest financing transaction

    —

    172,675

    Net proceeds from issuance of common stock under ATM facility

    —

    14,073

    Net cash provided by financing activities

    182,774

    367,580

    Net (decrease) increase in cash and cash equivalents and restricted cash

    (84,131
    )

    228,366

    Cash and cash equivalents and restricted cash – beginning of period

    384,256

    155,890

    Cash and cash equivalents and restricted cash – end of period
     
    $
    300,125

    $
    384,256

    Supplemental disclosure of cash flow information

    Interest paid
     
    $
    17,293

    $
    11,133

    Supplemental disclosure of noncash investing and financing activities:

    Property and equipment purchases included in accounts payable and accrued expenses
     
    $
    8

    $
    18

    Final interest payment fee
     
    $
    1,800

    $
    2,200

    Settlement of ESPP liability in common stock
     
    $
    2,401

    $
    1,417

    Settlement of 401(k) liability in common stock
     
    $
    3,683

    $
    1,612

See accompanying notes.

F-7

PHATHOM PHARMACEUTICALS, INC.